Finally, also in breast cancer, the characterization of CTCs in the subtype named triple negative breast cancer patients, which frequently metastasize to the brain, identified HER2 positivity as a hallmark of tumor progression (120). This evidence concerns the gene ERBB2 and neoplasm.